Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: Effect over CD4 expression on T cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 4, 2006, Pages 443-450

  De Leòn, Joel ^a   Fernández, Audry ^a   Mesa, Circe ^a   Clavel, Marilyn ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

CD4 down modulation; Immune dysfunction; NGcGM3 ganglioside; Tumour immunology

Indexed keywords

CD4 ANTIGEN; GANGLIOSIDE GM3; N GLYCOLOYLNEURAMINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; GANGLIOSIDOSIS; IMMUNOSURVEILLANCE; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; PROTEIN TARGETING; PROTEIN VARIANT; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD4; CELL CULTURE TECHNIQUES; DOWN-REGULATION; G(M3) GANGLIOSIDE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOPLASMS; NEURAMINIDASE; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 30444446808     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0041-6     Document Type: Article

References (36)

1. Bardor M, Nguyen DH, Diaz S, Varki A (2005) Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 280:4228-4237
2. Birklé S, Zeng G, Gao L, Yu RK, Aubry J (2003) Role of tumour-associated gangliosides in cancer progression. Biochimistry 85:455-463
3. Black PH (1980) Shedding from normal and cancer-cell surfaces. N Engl J Med 303:1415-1416
4. Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest Suppl 97:77-89
5. Caldwell S, Heitger A, Shen W, Liu Y, Taylor B, Ladisch S (2003) Mechanisms of ganglioside inhibition of APC function. J Immunol 171:1676-1683
6. Carr A, Mullet A, Mazorra Z, Vazquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, Fernández LE (2000) A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumours. Hybridoma 19:241-247
7. Carr A, Rodriguez E, Arango Mdel C, Camacho R, Osorio M, Gabri M, Carrillo G, Valdes Z, Bebelagua Y, Perez R, Fernandez LE (2003) Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 21:1015-1021
8. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95:11751-11756
9. Dolo V, Li R, Dillinger M, Flati S, Manel J, Taylor BJ, Pavan A, Ladisch S (2000) Enrichment and localization of ganglioside GD3 and caveolin-1 in shed tumour cell membrane vesicles. Biochim Biophys Acta 1486:265-274
10. Dumontet C, Rebbaa A, Bienvenu J, Portoukalian J (1994) Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. Cancer Immunol Immunother 38:311-316
11. Folch PJ, Arsove S, Meath JA (1951) Isolation of brain stradin: a new type of large molecular tissue component. J Biol Chem 191:819-831
12. Garofalo T, Sorice M, Misasi R, Cinque B, Giammatteo M, Pontieri GM, Cifone MG, Pavan A (1998) A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. J Biol Chem 273:35153-35160
13. Garofalo T, Sorice M, Misasi R, Cinque B, Mattei V, Pontieri GM, Cifone MG, Pavan A (2002) Ganglioside GM3 activates ERKs in human lymphocytic cells. J Lipid Res 43:971-978
14. Glebov OO, Nichols BJ (2004) Lipid raft proteins have a random distribution during localized activation of the T-cell receptor. Nat Cell Biol 6:238-243
15. Higashi H, Sasabe T, Fukui Y, Maru M, Kato S (1988) Detection of gangliosides as N-glycolylneuraminic acid-specific tumour-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 79:952-956
16. Irani DN, Lin KI, Griffin DE (1996) Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 157:4333-4340
17. Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A (1998) The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273:15866-15871
18. Kanda N (1999) Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 256:41-44
19. Kawaguchi T, Nakakuma H, Kagimoto T, Shirono K, Horikawa K, Hidaka M, Iwamori M, Nagai Y, Takatsuki K (1989) Characteristic mode of action of gangliosides in selective modulation of CD4 on human T lymphocytes. Biochem Biophys Res Commun 158(3):1050-1059
20. Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC (2004) Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 172:7821-7831
21. Kudo D, Rayman P, Horton C, Cathcart MK, Bukowski RM, Thornton M, Tannenbaum C, Finke JH (2003) Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumour-induced apoptosis of T cells. Cancer Res 63:1676-1683
22. Ladisch S, Wu ZL, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R (1987) Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39:73-76
23. Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165-5171
24. Martin M, Schneider H, Azouz A, Rudd CE (2001) Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med 194:1675-1681
25. McKallip R, Li R, Ladisch S (1999) Tumour gangliosides inhibit the tumour-specific immune response. J Immunol 163:3718-3726
26. Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Itomi S, Kannagi R (1990) Abnormal ocurrence and the differentiation dependent distribution of N-acetyl and N-glycolyl species of ganglioside GM2 in human germ cell tumours. Cancer 65:499-505
27. Muthing J, Steuer H, Peter-Katalinic J, Marx U, Bethke U, Neumann U, Lehmann J (1994) Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J Biochem (Tokyo) 116:64-73
28. Péguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J (2003) Gangliosides from human melanoma tumours impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170:3488-3494
29. Saggioro D, Sorio C, Calderazzo F, Callegaro L, Panozzo M, Berton G, Chieco-Bianchi L (1993) Mechanism of action of the monosialoganglioside GM1 as a modulator of CD4 expression. J Biol Chem 268:1368-1375
30. Sharom FJ, Chiu AL, Ross TE (1990) Gangliosides and glycophorin inhibit T-lymphocyte activation. Biochem Cell Biol 68:735-744
31. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM Jr (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363-369
32. Sorice M, Pavan A, Misasi R, Sansolini T, Garofalo T, Lenti L, Pontieri GM, Frati L, Torrisi MR (1995) Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes. Scand J Immunol 41:148-156
33. Svennerholm L (1957) Quantitative estimation of sialic acid: a colorimetric resorcinol-hydrocloridric acid method. Biochim Byophys Acta 24:604-611
34. Svennerholm L, Fredmand P (1980) A procedure for the quantitative isolation of brain gangliosides. Biochim Byophys Acta 617:97-109
35. Takahashi K, Ono K, Hirabayashi Y, Taniguchi M (1988) Escape mechanisms of melanoma from immune system by soluble melanoma antigen. J Immunol 140(9):3244-3248
36. Taniguchi M, Sakatsume M, Harada Y, Nores GA, Hakomori S (1988) Analysis of melanoma antigen and its involvement in tumour-escape mechanisms. Princess Takamatsu Symp 19:247-254